There are currently 1241 clinical trials in Nashville, Tennessee looking for participants to engage in research studies. Trials are conducted at various facilities, including Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University and Sarah Cannon Research Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Study of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to ER+/HER-2- Breast Cancer
NCT05386108
Recruiting
This is a multi-site, global, open-label study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases
Register for Updates
Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial
NCT05478304
Recruiting
This trial is a prospective, randomized, multicenter, multinational, blinded, superiority trial. The objective of this trial is to evaluate the effectiveness of left atrial appendage exclusion (LAAE) for the prevention of ischemic stroke or systemic arterial embolism in subjects undergoing cardiac surgery who have risk factors for atrial fibrillation and ischemic stroke.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Centennial Medical Center (TriStar), Nashville, Tennessee +1 locations
Conditions: Ischemic Stroke, Systemic Embolism
Register for Updates
Depressed Mood Improvement Through Nicotine Dosing 3
NCT05746273
Recruiting
Deficits in cognitive control are core features of late-life depression (LLD), contributing both to emotion dysregulation and problems with inhibiting irrelevant information, conflict detection, and working memory. Clinically characterized as executive dysfunction, these deficits are associated with poor response to antidepressants and higher levels of disability. Improvement of cognitive control network (CCN) dysfunction may benefit both mood and cognitive performance, however no current pharma... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/08/2025
Locations: Vanderbilt Psychiatric Hosptial, Nashville, Tennessee
Conditions: Depressive Disorder
Register for Updates
Depressed Mood Improvement Through Nicotine Dosing-3 (Depressed MIND3) Extension
NCT05746546
Recruiting
Deficits in cognitive control are core features of late-life depression (LLD), contributing both to emotion dysregulation and problems with inhibiting irrelevant information, conflict detection, and working memory. Clinically characterized as executive dysfunction, these deficits are associated with poor response to antidepressants and higher levels of disability. Improvement of cognitive control network (CCN) dysfunction may benefit both mood and cognitive performance, however no current pharma... Read More
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/08/2025
Locations: Vanderbilt Psychiatric Hospital, Nashville, Tennessee
Conditions: Depressive Disorder
Register for Updates
Abbott Ventricular Tachycardia PAS
NCT05839873
Recruiting
This post-approval study (PAS) is designed to provide continued clinical evidence to confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter, Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a post-market environment. This is a prospective, single arm, open-label, multi-center, observational study.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
07/08/2025
Locations: Vanderbilt Heart & Vascular Institute, Nashville, Tennessee
Conditions: Ventricular Tachycardia
Register for Updates
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
NCT06028074
Recruiting
GIM-122 is a first-in-class, humanized immunoglobulin G1 kappa dual functioning monoclonal antibody (DFA). This phase 1 / 2 study plans to evaluate the safety, tolerability, pharmacokinetics and clinical efficacy of intravenous (IV) administration of GIM-122 in adults with advanced malignancies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Tennessee Oncology, PLLC, Nashville, Tennessee
Conditions: Advanced Solid Malignancies
Register for Updates
Safer Storage Safer Homes An Inpatient Pediatric Lethal Means Counseling Pilot Trial
NCT06479889
Recruiting
Firearm injuries are the leading cause of death for American youth. Strikingly, firearm suicide among adolescents is growing faster than other groups. Lethal means counseling is standard of care, however, infrequently occurs despite pediatricians recognizing the importance. Lack of time, topic discomfort, and inadequate resources for families are commonly reported barriers to counseling. By addressing these factors, we can improve counseling with the ultimate goal of increasing safe storage and... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Monroe Carell Jr Children's Hospital at Vanderbilt, Nashville, Tennessee
Conditions: Firearm Injury, Hospitalizations Psychiatric
Register for Updates
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
NCT06492616
Recruiting
The primary goal of this study is to evaluate the effectiveness of elacestrant versus standard endocrine therapy in participants with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer with high risk of recurrence.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee +2 locations
Conditions: Breast Cancer
Register for Updates
Abbott Medical - VERITAS Study
NCT06707688
Recruiting
The primary objective of this study is to evaluate the safety and effectiveness of Abbott's Amulet™ 2 Left Atrial Appendage (LAA) occluder device (Amulet 2 device) in patients who have non-valvular atrial fibrillation and who are at increased risk for stroke and systemic embolism and have appropriate rationale to seek a non-pharmacologic alternative to oral anticoagulation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Vanderbilt Heart & Vascular Institute, Nashville, Tennessee
Conditions: Atrial Fibrillation (AF), Stoke
Register for Updates
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease
NCT06557772
Recruiting
This is a Phase 2a/b, randomized, double-blind, placebo-controlled, parallel-group, 6-arm study to evaluate the efficacy and safety of amlitelimab in adult participants with non-responsive celiac disease (NRCD) who are on a gluten free diet (GFD) with and without simulated inadvertent gluten exposure (SIGE). The primary purpose of this study is to demonstrate the efficacy of subcutaneous (SC) amlitelimab in male and female participants (aged 18 to 75 years, inclusive) with NRCD. The study will... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/07/2025
Locations: Quality Medical Research- Site Number : 8400018, Nashville, Tennessee
Conditions: Coeliac Disease, Celiac Disease
Register for Updates
A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer
NCT06562543
Recruiting
High blood pressure (hypertension) is a known side effect of the treatment with fruquintinib. Current research does not provide a clear answer whether minority groups such as Black/African American and/or Hispanic/Latino with refractory metastatic colorectal cancer (mCRC) have a bigger risk of higher blood pressure after treatment with fruquintinib. The main aim of this study is to learn how often adults of a minority group experience hypertension after they have been treated with fruquintinib f... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: Vanderbilt University Medical Center, Nashville, Tennessee
Conditions: Colorectal Cancer
Register for Updates
Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors
NCT06573294
Recruiting
The purpose of this trial is to study the antibody GEN1057 when used as a single agent for the treatment of certain types of cancer. Trial details include: * The trial duration will be up to approximately 11 months. * The treatment duration will be up to approximately 4 months (the duration of treatment may vary for each participant) and the follow-up duration will be approximately 6 months. Participation in the trial will require visits to the site. All participants will receive active drug;... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/07/2025
Locations: SCRI Oncology Partners, Nashville, Tennessee
Conditions: Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor
Register for Updates